411 related articles for article (PubMed ID: 16167154)
1. 18F-FDG PET in the management of endometrial cancer.
Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
[TBL] [Abstract][Full Text] [Related]
2. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
Grueneisen J; Sawicki LM; Wetter A; Kirchner J; Kinner S; Aktas B; Forsting M; Ruhlmann V; Umutlu L
Eur J Radiol; 2017 Apr; 89():14-19. PubMed ID: 28267530
[TBL] [Abstract][Full Text] [Related]
4. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.
Signorelli M; Guerra L; Buda A; Picchio M; Mangili G; Dell'Anna T; Sironi S; Messa C
Gynecol Oncol; 2009 Nov; 115(2):231-5. PubMed ID: 19695685
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
7. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
[TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
9. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
11. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
Kirchner J; Sawicki LM; Suntharalingam S; Grueneisen J; Ruhlmann V; Aktas B; Deuschl C; Herrmann K; Antoch G; Forsting M; Umutlu L
PLoS One; 2017; 12(2):e0172553. PubMed ID: 28225831
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
14. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
15. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
[TBL] [Abstract][Full Text] [Related]
17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Lin KJ; Lin WJ; Fu YK; Lin CY
J Nucl Med; 2005 Mar; 46(3):405-10. PubMed ID: 15750151
[TBL] [Abstract][Full Text] [Related]
19. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
[TBL] [Abstract][Full Text] [Related]
20. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
